Johnson & Johnson (NYSE:JNJ) Shares Sold by Advisory Resource Group

Advisory Resource Group trimmed its position in Johnson & Johnson (NYSE:JNJ) by 96.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,218 shares of the company’s stock after selling 32,284 shares during the period. Advisory Resource Group’s holdings in Johnson & Johnson were worth $202,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. MRP Capital Investments LLC boosted its position in shares of Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock worth $237,000 after acquiring an additional 65 shares during the last quarter. Syverson Strege & Co raised its holdings in Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock valued at $202,000 after buying an additional 65 shares during the period. Werba Rubin Papier Wealth Management lifted its position in Johnson & Johnson by 3.3% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock valued at $301,000 after buying an additional 66 shares in the last quarter. Denali Advisors LLC grew its stake in Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock worth $742,000 after buying an additional 67 shares during the period. Finally, Sage Mountain Advisors LLC increased its position in shares of Johnson & Johnson by 0.5% in the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock worth $2,106,000 after acquiring an additional 67 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research reports. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Leerink Partners cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Bank of America dropped their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, April 10th. Raymond James Financial decreased their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Finally, Morgan Stanley lifted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Stock Down 0.6%

JNJ stock opened at $149.81 on Friday. The firm has a market cap of $360.44 billion, a price-to-earnings ratio of 16.66, a PEG ratio of 2.28 and a beta of 0.42. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The firm has a fifty day moving average price of $154.07 and a two-hundred day moving average price of $153.63. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.47%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.